INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Gheuens Sarah reported AGIO

Chief Medical Officer · AGIOS PHARMACEUTICALS, INC. · Common stock

Side
M
Value
$13K
Shares
500
Price
$25.01
Executed
Oct 22, 2026
Disclosed
Oct 23, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Oct 22 executedOct 23, 2026 disclosed

AGIO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

$13K reported value · 0.9% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · AGIO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    7
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M—
    7,866 sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    11
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$296K
    7,866 sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    2
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M$197K
    7,866 sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    8
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$56K
    1,489 sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    1
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$19K
    500 sh
    		Oct 22, 2026Oct 23, 2026
    traded Oct 22, 2026
    		+1dSEC FORM 4

    Evidence

    0
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M—
    500 sh
    		Oct 22, 2026Oct 23, 2026
    traded Oct 22, 2026
    		+1dSEC FORM 4

    Evidence

    3
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M—
    1,489 sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    0
    GS
    Gheuens SarahChief Medical Officer
    AGIOAGIOS PHARMACEUTICALS, INC.
    Option exercise · 10b5-1 plan
    		M$37K
    1,489 sh
    		Oct 21, 2026Oct 23, 2026
    traded Oct 21, 2026
    		+2dSEC FORM 4

    Evidence

    20
    Gilbert Ray Cisneros, Jr.DSelf
    AGIOAGIOS PHARMACEUTICALS, INC.
    Purchase
    		BUY$1,001 – $15KAug 20, 2026Sep 10, 2026
    traded Aug 20, 2026
    		+21dHOUSE PTR

    Evidence

    28
    Gilbert Ray Cisneros, Jr.DSelf
    AGIOAGIOS PHARMACEUTICALS, INC.
    Purchase
    		BUY$1,001 – $15KMar 3, 2026Apr 7, 2026
    traded Mar 3, 2026
    		+35dHOUSE PTR

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001439222-26-000122
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 22, 2026
    Published
    Oct 23, 2026
    Ingested by INSIDER
    Nov 5, 02:09 UTC
    Last re-read
    Nov 5, 02:09 UTC

    Extracted facts

    Filer
    Gheuens Sarah
    Role
    Chief Medical Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    AGIOS PHARMACEUTICALS, INC.
    Ticker
    AGIO
    Shares
    500
    Price per share
    $25.01
    Value
    $12,505
    Execution date (reported)
    Oct 22, 2026
    Owned after transaction
    55.1K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 500
    • Price: $25.01

    = $12,505

    What this establishes

    Gheuens Sarah filed this Form 4 reporting a option exercise of AGIO on Oct 22, 2026. It became public on Oct 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Gheuens Sarahcik:0001881190
    Issuer
    AGIOS PHARMACEUTICALS, INC.cik:0001439222

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.